Beruflich Dokumente
Kultur Dokumente
DOI 10.1007/s13300-016-0208-5
REVIEW
alogliptin is a good option for reducing glycated periods of time (even years) before adding
hemoglobin (HbA1c) without significant additional therapy [4]. This step-up approach
hypoglycemia. is conducive to treatment failure; evidence from
Conclusion: Clinicians have a comprehensive monotherapy studies shows that long-term
armamentarium of medications to treat patients glycemic control is often not durable [5, 6].
with T2DM. Clinical evidence has shown that Several studies have stressed the importance of
dual or triple oral combination therapy is early treatment, not only to prevent small vessel
effective for glycemic control, and early disease complications, but to prevent
treatment is effective in getting patients to cardiovascular (CV) events years after the
goal more quickly. Use of SPCs is an option completion of the trial (a result of the legacy
for double or triple oral combination therapy effect) as well [79].
and may result in better adherence. The current therapeutic landscape also
results from caution based on potential
Keywords: DPP-4 inhibitors; Early adverse events with available glucose-lowering
combination therapy; Hyperglycemia; agents [4]. For example, insulins and
Hypoglycemia; Oral glucose-lowering agents; sulfonylureas (SUs) are associated with weight
SGLT2 inhibitors; Single-pill combination; gain and hypoglycemia [1], the latter being of
Type 2 diabetes mellitus particular concern in the elderly [10]. The
management of T2DM may be facilitated with
single-pill combinations (SPC) by enabling
INTRODUCTION patients to take fewer pills per day, which may
lead to improved patient adherence [11]. Many
Over the last several decades, the diabetes combinations include metformin and can be
landscape has been transformed by an used early in the disease. Two other SPCs,
improved understanding of its pioglitazone/alogliptin and empagliflozin/
pathophysiology and the development of an linagliptin, have shown good glucose-lowering
array of antihyperglycemic medications [1]. Yet, efficacy when added to metformin [12, 13].
diabetes remains a pervasive disease with It is important to choose agents that treat the
immense public health consequences and patient as a whole, not just their hyperglycemia.
increasing prevalence of type 2 diabetes For example, individuals with T2DM are at high
mellitus (T2DM) in adults [2]. Despite the risk of CV disease and need aggressive therapy
number of treatment options, hyperglycemia that includes the management of concomitant
is still often poorly controlled [3], chiefly CV risk factors such as obesity, hypertension,
reflecting the limitations inherent in and dyslipidemia [14]. In addition, patients
treatment options for T2DM and clinical with T2DM and chronic kidney disease (CKD)
inertia. Lifestyle changes such as diet or are also at an increased risk of severe
exercise are insufficient, and the efficacy of hypoglycemia [15] and present a treatment
pharmacologic agents is rarely sustained over challenge. Metformin is not recommended for
time and may be limited by side effects. After use in patients with an estimated glomerular
prescribing therapeutic lifestyle changes, there filtration rate (eGFR) less than 45 mL/min/
may be delays in initiating monotherapy, often 1.732; however, metformin may be used safely
metformin, and physicians may wait long in patients with mild impairment in kidney
Diabetes Ther (2016) 7:621639 623
Table 1 Classes of oral medications for glycemic management approved in the USA [1, 24]
Class Compounds Primary physiologic action Hypoglycemia Weight
Biguanides Metformin ; Hepatic glucose production Neutral Slight
loss
Sulfonylureas Glyburide/glibenclamide : Insulin secretion Moderate/severe Gain
Glimepiride
Glipizide
Meglitinides Repaglinide : Insulin secretion Mild Gain
Nateglinide
Thiazolidinediones Pioglitazone : Insulin sensitivity Neutral Gain
Rosiglitazone
a-Glucosidase Acarbose Slows carbohydrate digestion/absorption Neutral Neutral
inhibitors Miglitol
DPP-4 inhibitors Alogliptin : Insulin secretion (glucose-dependent) Neutral Neutral
Linagliptin ; Glucagon secretion (glucose-dependent)
Sitagliptin
Saxagliptin
Bile acid Colesevelam ; Hepatic glucose production (?) Neutral Neutral
sequestrants : Incretin levels (?)
Dopamine-2 Bromocriptine (quick Modulates hypothalamic regulation of Neutral Neutral
agonists release) metabolism
: Insulin sensitivity
SGLT2 inhibitors Canagliozin Inhibit glucose reabsorption by the kidney Neutral Loss
Dapagliozin : Glucosuria
Empagliozin
DPP-4 dipeptidyl peptidase-4, SGLT2 sodium glucose cotransporter 2
tract exhibits abnormal secretion of incretin during fasting, and reabsorbing all of the
hormones, glucagon-like peptide 1 (GLP-1) and filtered glucose [21], both of which are
glucose-dependent insulinotropic polypeptide adaptive mechanisms that ensure sufficient
[18, 20]. These two hormones account for 90% energy is available during fasting periods. The
of the incretin effect, which plays a pivotal role transport protein, SGLT2, is a low-affinity,
in maintaining normal glucose homeostasis. high-capacity glucose transporter that
The kidneys also play a crucial role in glucose reabsorbs approximately 90% of filtered
homeostasis by releasing glucose into the glucose, while the high-affinity, low-capacity
circulation via gluconeogenesis, particularly SGLT1 transporter reabsorbs the remainder [22].
Diabetes Ther (2016) 7:621639 625
Fig. 1 Pathophysiologic abnormalities targeted by cur- triumvirate to the ominous octet: a new paradigm for the
rently available antihyperglycemic medications. DPP4i treatment of type 2 diabetes mellitus. American Diabetes
dipeptidyl peptidase 4 inhibitor, GLP1 RA glucagon-like Association, 2009. Copyright and all rights reserved.
peptide 1 receptor agonist, HGP hepatic glucose produc- Material from this publication has been used with the
tion, MET metformin, SGLT2i sodium glucose cotrans- permission of the American Diabetes Association
porter 2 inhibitor, TZD thiazolidinedione. From the
Linagliptin ? metformin XR Jentadueto XR (Boehringer Ingelheim Pharmaceuticals, 2.5/1000 XR5/1000 XR Once daily
Inc.)
Saxagliptin ? metformin XR Kombiglyze XR (AstraZeneca Pharmaceuticals, LP) 2.5/1000 XR5/500 XR5/1000 XR Once daily
Sitagliptin ? metformin Janumet (Merck Sharp & Dohme Corp.) 50/50050/1000 Twice daily
Sitagliptin ? metformin XR Janumet XR (Merck Sharp & Dohme Corp.) 50/500 XR50/1000 XR100/1000 XR Once daily
SGLT2 inhibitor ? metformin
Canagliozin ? metformin Invokamet (Janssen Pharmaceuticals, Inc.) 50/50050/1000150/500150/1000 Twice daily
Canagliozin ? metformin Invokamet XR (Janssen Pharmaceuticals, Inc.) 50/500 XR50/1000 XR150/500 XR150/ Once daily
XR 1000 XR
Dapagliozin ? metformin Xigduo XR (AstraZeneca Pharmaceuticals, LP) 5/500 XR5/1000 XR10/500 XR10/1000 Once daily
XR XR
Empagliozin ? metformin Synjardy (Boehringer Ingelheim Pharmaceuticals, Inc.) 5/500 5/1000 12.5/500 12.5/1000 Twice daily
TZD ? metformin
Pioglitazone ? metformin Actoplus Met (Takeda Pharmaceuticals America, Inc.) 15/50015/850 Twice daily
Pioglitazone ? metformin Actoplus Met XR (Takeda Pharmaceuticals America, Inc.) 15/100030/1000 Once daily
XR
Rosiglitazone ? metformin Avandamet (GlaxoSmithKline) 2/5004/5002/104/1000 Twice daily
SU ? metformin
Glyburide ? metformin Generic 2.5/5005/500 Twice daily
Combinations without metformin
DPP-4 inhibitor ? TZD
627
628 Diabetes Ther (2016) 7:621639
Please consult full prescribing information for contraindications, warnings and precautions, and dosage and administration for use in specic populations (e.g., renal
DPP-4 dipeptidyl peptidase 4, SGLT2 sodium glucose cotransporter 2, SU sulfonylurea, T2DM type 2 diabetes mellitus, TZD thiazolidinedione, XR extended
inappropriately increased glucose reabsorption
Once daily
Once daily
Once daily
Once daily
found in T2DM and increasing urinary glucose
excretion [38]. SGLT2 inhibitors have proven to
be effective not only in improving glycemic
management but also in decreasing weight and
reducing systolic blood pressure (BP), with a low
12.5/1512.5/3012.5/4525/1525/
10/525/5
30/230/4
impairment)
CV disease [65]. The results reassuringly heart failure (HR, 0.65; 95% CI, 0.500.85;
demonstrated no increased risk versus placebo P = 0.002), and death from any cause (HR,
for the primary composite CV endpoint of CV 0.68; 95% CI, 0.570.82; P\0.001). Among
death, nonfatal MI, nonfatal stroke, or patients receiving empagliflozin, there was an
hospitalization for unstable angina (alogliptin, increased rate of genital infection but no
9.6%, placebo, 9.6%; HR, 0.98; 95% CI, increase in other adverse events.
0.881.09; P\0.001 for non-inferiority in the
per-protocol population; P = 0.65 for CV Outcomes Trials with TZDs
superiority) and no increase in hospitalization
for heart failure [HR in the intent-to-treat The TZDs are among the most potent
analysis: 1.00 (95% CI, 0.831.20); P = 0.98] insulin-sensitizing drugs available. Their use in
[65]. patients with T2DM has decreased mainly as a
result of the adverse CV outcomes attributed to
CV Outcomes Trials with SGLT2 Inhibitors rosiglitazone [68]. Pioglitazone, the other agent
in this class, may reduce the risk of CV events,
Ongoing clinical trials assessing the impact of including stroke [69]. The PROspective
the SGLT2 inhibitors dapagliflozin and PioglitAzone Clinical Trial In macro-Vascular
canagliflozin in patients with T2DM at high Events (PROactive) trial evaluated the addition
risk of CV complications include Dapagliflozin of pioglitazone to current therapy in patients
Effect on CardiovascuLAR Events with T2DM and a history of macrovascular
(DECLARE-TIMI 58) [41] and CANagliflozin disease (N = 5238). Although the trial failed to
cardioVascular Assessment Study (CANVAS) meet its primary composite endpoint of death
[66, 67]. For empagliflozin, the recently from any cause, nonfatal MI, stroke, acute
completed EMPA-REG OUTCOME trial is the coronary syndrome, leg amputation, coronary
first dedicated CV outcome study to demonstrate revascularization, or revascularization of the
that a glucose-lowering agent can improve CV leg, a significant reduction in the composite
endpoints and lower CV mortality as well as secondary endpoint was observed (death from
all-cause mortality in patients with T2DM at any cause, nonfatal MI, or nonfatal stroke: HR
high risk of CV events [42]. It evaluated the 0.84; 95% CI, 0.720.98; P = 0.027) [70]. In a
effects of empagliflozin (10 or 25 mg once daily follow-up analysis, the pioglitazone reduced
versus placebo) on top of standard of care on CV rates of fatal or nonfatal stroke and the
outcomes in 7020 patients with T2DM at high composite of CV death, nonfatal stroke, or MI
risk of CV disease. The primary outcome was a among patients with a history of previous stroke
composite of death from CV causes, nonfatal MI, [69]. More recently, pioglitazone was also found
or nonfatal stroke (3-point major adverse to lower the risk of stroke or MI in individuals
cardiovascular events or MACE) and was without diabetes who had insulin resistance
significantly reduced with empagliflozin (HR, along with ischemic stroke or transient
0.86, 95% CI, 0.740.99; P\0.001 for ischemic attacks [71]. Although pioglitazone
non-inferiority and P = 0.04 for superiority). has shown beneficial CV outcomes, other
Empagliflozin resulted in significantly lower studies with the long-term use of TZDs,
rates of death from CV causes (HR, 0.62; 95% mainly rosiglitazone [48, 72], have shown no
CI, 0.490.77; P\0.001), hospitalization for superiority.
632 Diabetes Ther (2016) 7:621639
SPCs may be less frequently prescribed because 24 weeks was higher with empagliflozin
they are associated with the disadvantages of 25 mg/linagliptin 5 mg (55.4%) and
SUs; namely, lack of glycemic durability, empagliflozin 10 mg/linagliptin 5 mg (62.3%)
hypoglycemia, and weight gain [25]. The third versus empagliflozin alone (25 mg, 41.5%;
type of SPC therapy contains neither metformin 10 mg, 38.8%) or linagliptin alone (5 mg,
nor an SU; these agents can be added to 32.3%) [88]. In this trial, however, the
metformin when metformin alone is no longer empagliflozin 25 mg/linagliptin 5 mg SPC was
sufficient. There are only two such SPCs not significantly better than empagliflozin
approved by the US FDA: pioglitazone/ 25 mg alone. When compared with linagliptin
alogliptin [Oseni (Takeda Pharmaceuticals 5 mg alone, both SPC doses significantly
America, Inc.)] and empagliflozin/linagliptin reduced HbA1c, suggesting that without
[Glyxambi (Boehringer Ingelheim metformin the glucose reduction is mostly
Pharmaceuticals, Inc.)] [87]. The combination driven by empagliflozin [88]. Body weight
of dapagliflozin/saxagliptin was submitted for reductions with the SPCs were also similar to
FDA review, and the FDA has asked for empagliflozin alone, as were systolic BP
additional data. reductions from baseline (2.12.5 mmHg) and
a low incidence of hypoglycemia.
Empagliflozin/Linagliptin SPC In both of these trials, events consistent with
urinary tract infections occurred at comparable
When treatment with metformin alone is not rates across all groups (1016%), and events
sufficient, the empagliflozin/linagliptin SPC can consistent with genital infection were present
provide better HbA1c reductions than in 28.5% of patients, mostly women. In
empagliflozin or linagliptin alone. In a summary, the empagliflozin/linagliptin SPC is
placebo-controlled study (n = 674), 61.8% and well tolerated, may cause a modest weight loss
57.8% of patients with baseline HbA1c of at with lower systolic BP, and has a low rate of
least 7.0% achieved an HbA1c of less than 7.0% hypoglycemia.
at week 24 with empagliflozin 25 mg/linagliptin
5 mg and empagliflozin 10 mg/linagliptin 5 mg, Pioglitazone/Alogliptin SPC
respectively, versus 28.036.1% of patients who
were using any of the three agents alone [13]. Another available SPC is pioglitazone plus
Even greater HbA1c reductions were achieved in alogliptin. In drug-nave patients, the
individuals with a baseline HbA1c of at least combination with pioglitazone 30 mg/
8.5%, and these improvements in glycemic alogliptin 25 mg resulted in greater reductions
control were associated with weight loss and in HbA1c (-1.7 0.1% from an 8.8% mean
reduced systolic BP [13]. baseline) versus pioglitazone 30 mg
The empagliflozin/linagliptin SPC may be a (-1.2 0.1%, P\0.001) or alogliptin 25 mg
good alternative when metformin is not (-1.0 0.1%, P\0.001) alone [89]. When
indicated or tolerated or in treatment-nave added to metformin, the pioglitazone/
individuals. In treatment-nave patients with alogliptin SPC was also well tolerated and
T2DM and moderate hyperglycemia (n = 677; effective [12]. When administered to
mean HbA1c, 8.0%), the proportion who individuals with HbA1c 7.510.0% receiving at
achieved HbA1c levels less than 7.0% at least 1500 mg/day of metformin, pioglitazone
634 Diabetes Ther (2016) 7:621639
plus metformin (pooled group) achieved a Several CV outcomes trials have been
mean HbA1c reduction from baseline of 0.9%. completed for the individual glucose-lowering
In contrast, participants receiving triple therapy agents. CV outcomes trials for sitagliptin,
(alogliptin, pioglitazone, and metformin) saxagliptin, and alogliptin have shown no
achieved a mean HbA1c reduction of 1.4% increased risk of overall CV events. EMPA-REG
(P\0.001 versus the pioglitazone plus OUTCOME is the only trial that has
metformin pooled group). demonstrated that adding empagliflozin causes
a reduction in major adverse CV events,
all-cause mortality, CV mortality, and heart
CONCLUSIONS
failure, as well as an improvement in renal
Antihyperglycemic SPCs have been developed outcomes, when compared to treatment
in an effort to address the issues of adherence placebo on top of the current recommended
associated with combination pharmacotherapy standard of care [42, 43]. In a post hoc analysis
for patients with T2DM, with the goal of pioglitazone has also been found to have
optimizing clinical outcomes. Most SPCs favorable CV outcomes when used for
contain metformin or an SU. On the basis of secondary intervention when compared to
current guidelines, metformin is the preferred placebo [69, 70]. In summary, we now have
choice for one of the agents in combination different choices in the selection of oral agents
therapy. The use of SUs is less desirable because available for management of hyperglycemia.
of weight gain, hypoglycemia, and potential CV While the treatment choice needs to be
risks. When considering orally administered patient-centered, we now have medications
alternatives or additions to metformin that in addition to glycemic control also
therapy, agents with a low risk of reduce CV outcomes.
hypoglycemia that provide weight neutrality Early diagnosis of T2DM and aggressive
or weight loss and have a proven CV safety glycemic treatment may help preserve b cell
profile are preferred. function. In addition, clinical studies suggest
In the USA, two non-metformin that aggressive and early glycemic therapy
combinations are available, reduces complications, and the use of lifestyle
alogliptin/pioglitazone and linagliptin/ changes together with initial combination
empagliflozin. Both combinations contain therapy is recommended. Clinicians now have
DPP-4 inhibitors, which are associated with a choice of what to use initially with
weight neutrality. However, when used in metformin, or what to add when metformin
combination, linagliptin/empagliflozin is fails. Newer combinations are weight neutral or
associated with weight loss due to the SGLT2 may provide weight loss. Adding an SPC may
component, and alogliptin/pioglitazone is improve adherence by decreasing the number
associated with weight gain due to the TZD of pills needed. Finally, the cost of expensive
component. These combinations are associated newer medications must be measured along
with a low risk of hypoglycemia (except when with the potential costs of complications
used in conjunction with insulin or insulin associated with older medications. For
secretagogues). Neither combination has been example, sulfonylureas are associated with
studied in a dedicated CV outcomes trial. hypoglycemia, and medical interventions for
Diabetes Ther (2016) 7:621639 635
hypoglycemia often require more monitoring Pharmaceuticals North America, Inc, Sanofi,
and sometimes costly hospitalizations [90]. and Boehringer Ingelheim. P-H Groop
In managing diabetes, early diagnosis and Per-Henrik Groop has received lecture
treatment with better lifestyles and proper honoraria from AstraZeneca, Boehringer
medications can normalize HbA1c without Ingelheim, Eli Lilly, Genzyme, MSD, Novartis,
hypoglycemia and/or weight gain. The use of Novo Nordisk; has received
SPC therapy is recommended for better investigator-initiated grants from Eli Lilly and
adherence, and a more aggressive early Roche; and is a member of advisory boards for
treatment should result in fewer complications AbbVie, Boehringer Ingelheim, Cebix, Eli Lilly,
and a better quality of life. Consideration is Janssen, Medscape, MSD, Novartis, and Sanofi.
needed in every case to provide a
patient-centered approach that treats the Compliance with Ethics Guidelines. This
patient as a whole. This necessarily includes article is based on previously conducted
taking into account concomitant risk factors studies and does not involve any new studies
such as obesity, hypertension, dyslipidemia, of human or animal subjects performed by any
and renal impairment, as well as addressing of the authors.
medication riskbenefit profiles and costs, when
Open Access. This article is distributed
making treatment choices.
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
ACKNOWLEDGEMENTS License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommer-
No funding or sponsorship was received for this cial use, distribution, and reproduction in any
study or publication of this article. Editorial medium, provided you give appropriate credit
support for this manuscript was provided by to the original author(s) and the source, provide
Linda Merkel, PhD, of Envision Scientific a link to the Creative Commons license, and
Solutions, which was contracted and funded indicate if changes were made.
by Boehringer Ingelheim Pharmaceuticals, Inc.
(BIPI). BIPI was given the opportunity to review
the manuscript for medical and scientific REFERENCES
accuracy as well as intellectual property
considerations. The authors retained complete 1. Inzucchi SE, Bergenstal RM, Buse JB, et al.
Management of hyperglycemia in type 2 diabetes,
and final authority of this manuscript. All 2015: a patient-centered approach. Update to a
named authors meet the International position statement of the American Diabetes
Association and the European Association for the
Committee of Medical Journal Editors (ICMJE) Study of Diabetes. Diabetes Care. 2015;38(1):1409.
criteria for authorship for this manuscript, take
2. Centers for Disease Control. Diabetes Report Card.
responsibility for the integrity of the work as a 2014. http://www.cdc.gov/diabetes/pdfs/library/
whole, and have given final approval for the diabetesreportcard2014.pdf. Accessed 25 Aug 2015.
version to be published. 3. Ali MK, Bullard KM, Saaddine JB, Cowie CC,
Imperatore G, Gregg EW. Achievement of goals in
U.S. diabetes care, 19992010. N Engl J Med.
Disclosures. J Zonszein is a consultant or 2013;368(17):161324.
speaker for Novo Nordisk, Takeda
636 Diabetes Ther (2016) 7:621639
4. Khunti K, Wolden ML, Thorsted BL, Andersen M, 15. National Kidney Foundation. K/DOQI Clinical
Davies MJ. Clinical inertia in people with type 2 practice guidelines for chronic kidney disease:
diabetes: a retrospective cohort study of more than evaluation, classification and stratification. 2002.
80,000 people. Diabetes Care. 2013;36(11):34117. https://www.kidney.org/sites/default/files/docs/ckd_
evaluation_classification_stratification.pdf. Accessed
5. Kahn SE, Haffner SM, Heise MA, et al. Glycemic 25 Aug 2015.
durability of rosiglitazone, metformin, or glyburide
monotherapy. N Engl J Med. 16. US Food and Drug Administration. FDA Drug Safety
2006;355(23):242743. Communication: FDA revises warnings regarding
use of the diabetes medicine metformin in certain
6. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic patients with reduced kidney function. http://www.
control with diet, sulfonylurea, metformin, or fda.gov/Drugs/DrugSafety/ucm493244.htm Acces-
insulin in patients with type 2 diabetes mellitus: sed 18 April 2016.
progressive requirement for multiple therapies
(UKPDS 49). UK Prospective Diabetes Study 17. Gaede P, Oellgaard J, Carstensen B, et al. Years of
(UKPDS) Group. JAMA. 1999;281(21):200512. life gained by multifactorial intervention in
patients with type 2 diabetes mellitus and
7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil microalbuminuria: 21 years follow-up on the
HA. 10-year follow-up of intensive glucose control Steno-2 randomised trial. Diabetologia.
in type 2 diabetes. N Engl J Med. 2016;59(11):2298307.
2008;359(15):157789.
18. DeFronzo RA. Banting Lecture. From the
8. Hayward RA, Reaven PD, Wiitala WL, et al. triumvirate to the ominous octet: a new paradigm
Follow-up of glycemic control and cardiovascular for the treatment of type 2 diabetes mellitus.
outcomes in type 2 diabetes. N Engl J Med. Diabetes. 2009;58(4):77395.
2015;372(23):2197206.
19. Goyal A, Nimmakayala KR, Zonszein J. Is there a
9. Nathan DM, Cleary PA, Backlund JY, et al. Intensive paradox in obesity? Cardiol Rev.
diabetes treatment and cardiovascular disease in 2014;22(4):16370.
patients with type 1 diabetes. N Engl J Med.
2005;353(25):264353. 20. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ.
Secretion of glucagon-like peptide-1 (GLP-1) in type
10. Lipska KJ, Ross JS, Wang Y, et al. National trends in 2 diabetes: what is up, what is down? Diabetologia.
US hospital admissions for hyperglycemia and 2011;54(1):108.
hypoglycemia among Medicare beneficiaries, 1999
to 2011. JAMA Intern Med. 2014;174(7):111624. 21. Gerich JE. Role of the kidney in normal glucose
homeostasis and in the hyperglycaemia of diabetes
11. Lokhandwala T, Smith N, Sternhufvud C, mellitus: therapeutic implications. Diabet Med.
Sorstadius E, Lee WC, Mukherjee J. A 2010;27(2):13642.
retrospective study of persistence, adherence,
and health economic outcomes of fixed-dose 22. DeFronzo RA, Davidson JA, Del Prato S. The role of
combination vs. loose-dose combination of oral the kidneys in glucose homeostasis: a new path
anti-diabetes drugs. J Med Econ. 2016;19(3): towards normalizing glycaemia. Diabetes Obes
20312. Metab. 2012;14(1):514.
12. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki 23. Schwartz MW, Seeley RJ, Tschop MH, et al.
Q, Pratley RE. Efficacy and tolerability of the DPP-4 Cooperation between brain and islet in glucose
inhibitor alogliptin combined with pioglitazone, in homeostasis and diabetes. Nature.
metformin-treated patients with type 2 diabetes. 2013;503(7474):5966.
J Clin Endocrinol Metab. 2012;97(5):161522.
24. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/
13. DeFronzo RA, Lewin A, Patel S, et al. Combination ACE comprehensive diabetes management
of empagliflozin and linagliptin as second-line algorithm 2015. Endocr Pract. 2015;21(4):43847.
therapy in subjects with type 2 diabetes
inadequately controlled on metformin. Diabetes 25. American Diabetes Association. Standards of
Care. 2015;38(3):38493. medical care in diabetes-2015. Diabetes Care.
2015;38(Suppl):S193.
14. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH,
Pedersen O. Multifactorial intervention and 26. Knowler WC, Barrett-Connor E, Fowler SE, et al.
cardiovascular disease in patients with type 2 Reduction in the incidence of type 2 diabetes with
diabetes. N Engl J Med. 2003;348(5):38393. lifestyle intervention or metformin. N Engl J Med.
2002;346(6):393403.
Diabetes Ther (2016) 7:621639 637
27. Haas L, Maryniuk M, Beck J, et al. National 39. Scheen AJ. Pharmacodynamics, efficacy and safety
standards for diabetes self-management education of sodium-glucose co-transporter type 2 (SGLT2)
and support. Diabetes Care. 2014;37(Suppl inhibitors for the treatment of type 2 diabetes
1):S14453. mellitus. Drugs. 2015;75(1):3359.
28. Torres EA, Tiwari A, Movsas S, Carrasquillo I, 40. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh
Zonszein J. Underutilization of diabetes education: S. Genital and urinary tract infections in diabetes:
experience in an urban teaching hospital in the impact of pharmacologically-induced glucosuria.
Bronx. J Diabetes Metab Syndr Disord. 2015;2:005. Diabetes Res Clin Pract. 2014;103(3):37381.
29. Drucker DJ, Nauck MA. The incretin system: 41. Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M,
glucagon-like peptide-1 receptor agonists and Gupta A. Cardiovascular outcomes of
dipeptidyl peptidase-4 inhibitors in type 2 sodium-glucose cotransporter 2 inhibitors: a
diabetes. Lancet. 2006;368(9548):1696705. comprehensive review of clinical and preclinical
studies. Int J Cardiol. 2016;212:2936.
30. Jurczyk A, Diiorio P, Brostowin D, et al. Improved
function and proliferation of adult human beta 42. Zinman B, Wanner C, Lachin JM, et al.
cells engrafted in diabetic immunodeficient Empagliflozin, cardiovascular outcomes, and
NOD-scid IL2rgamma(null) mice treated with mortality in type 2 diabetes. N Engl J Med.
alogliptin. Diabetes Metab Syndr Obes. 2015;373(22):211728.
2013;6:4939.
43. Wanner C, Inzucchi SE, Lachin JM, et al.
31. Shah P, Ardestani A, Dharmadhikari G, et al. The Empagliflozin and progression of kidney disease in
DPP-4 inhibitor linagliptin restores beta-cell type 2 diabetes. N Engl J Med. 2016;375(4):32334.
function and survival in human isolated islets
through GLP-1 stabilization. J Clin Endocrinol 44. Rosenstock J, Ferrannini E. Euglycemic diabetic
Metab. 2013;98(7):E116372. ketoacidosis: a predictable, detectable, and
preventable safety concern with SGLT2 inhibitors.
32. Green JB. The dipeptidyl peptidase-4 inhibitors in Diabetes Care. 2015;38(9):163842.
type 2 diabetes mellitus: cardiovascular safety.
Postgrad Med. 2012;124(4):5461. 45. US Food and Drug Administration. FDA Drug Safety
Communication: FDA warns that SGLT2 inhibitors
33. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 for diabetes may result in a serious condition of too
receptor agonists and DPP-4 inhibitors: much acid in the blood. 2015. http://www.fda.gov/
meta-analysis and systematic review. Clin Ther. Drugs/DrugSafety/ucm446845.htm. Accessed 13
2012;34(6):124758, e22. July 2015.
34. Scheen AJ. Pharmacokinetics and clinical use of 46. Nathan DM, Buse JB, Kahn SE, et al. Rationale and
incretin-based therapies in patients with chronic design of the glycemia reduction approaches in
kidney disease and type 2 diabetes. Clin diabetes: a comparative effectiveness study
Pharmacokinet. 2015;54(1):121. (GRADE). Diabetes Care. 2013;36(8):225461.
35. Karagiannis T, Paschos P, Paletas K, Matthews DR, 47. Frye RL, August P, Brooks MM, et al. A randomized
Tsapas A. Dipeptidyl peptidase-4 inhibitors for trial of therapies for type 2 diabetes and coronary
treatment of type 2 diabetes mellitus in the artery disease. N Engl J Med. 2009;360(24):250315.
clinical setting: systematic review and
meta-analysis. BMJ. 2012;344:e1369. 48. Home PD, Pocock SJ, Beck-Nielsen H, et al.
Rosiglitazone evaluated for cardiovascular
36. US Food and Drug Administration. FDA Drug Safety outcomes in oral agent combination therapy for
Communication: FDA warns that DPP-4 inhibitors type 2 diabetes (RECORD): a multicentre,
for type 2 diabetes may cause severe joint pain. randomised, open-label trial. Lancet.
2015. http://www.fda.gov/Drugs/DrugSafety/ 2009;373(9681):212535.
ucm459579.htm. Accessed 28 Aug 2015.
49. Bennett WL, Maruthur NM, Singh S, et al.
37. Egan AG, Blind E, Dunder K, et al. Pancreatic safety Comparative effectiveness and safety of
of incretin-based drugsFDA and EMA assessment. medications for type 2 diabetes: an update
N Engl J Med. 2014;370(9):7947. including new drugs and 2-drug combinations.
Ann Intern Med. 2011;154(9):60213.
38. Bays H. Sodium glucose co-transporter type 2
(SGLT2) inhibitors: targeting the kidney to 50. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart
improve glycemic control in diabetes mellitus. disease and stroke statistics2015 update: a report
Diabetes Ther. 2013;4(2):195220.
638 Diabetes Ther (2016) 7:621639
from the American Heart Association. Circulation. the risk for major cardiovascular events and death.
2015;131(4):e29322. Can J Diabetes. 2015;39(5):3839.
51. Buse JB, Ginsberg HN, Bakris GL, et al. Primary 62. Scirica BM, Braunwald E, Raz I, et al. Heart failure,
prevention of cardiovascular diseases in people saxagliptin, and diabetes mellitus: observations
with diabetes mellitus: a scientific statement from from the SAVOR-TIMI 53 randomized trial.
the American Heart Association and the American Circulation. 2014;130(18):157988.
Diabetes Association. Diabetes Care.
2007;30(1):16272. 63. White WB, Cannon CP, Heller SR, et al. Alogliptin
after acute coronary syndrome in patients with type
52. Gaede P, Lund-Andersen H, Parving HH, Pedersen 2 diabetes. N Engl J Med. 2013;369(14):132735.
O. Effect of a multifactorial intervention on
mortality in type 2 diabetes. N Engl J Med. 64. Zannad F, Cannon CP, Cushman WC, et al. Heart
2008;358(6):58091. failure and mortality outcomes in patients with type
2 diabetes taking alogliptin versus placebo in
53. Lachin JM, Orchard TJ, Nathan DM. Update on EXAMINE: a multicentre, randomised,
cardiovascular outcomes at 30 years of the Diabetes double-blind trial. Lancet. 2015;385(9982):206776.
Control and Complications Trial/Epidemiology of
Diabetes Interventions and Complications study. 65. Green JB, Bethel MA, Armstrong PW, et al. Effect of
Diabetes Care. 2014;37(1):3943. sitagliptin on cardiovascular outcomes in type 2
diabetes. N Engl J Med. 2015;373(3):23242.
54. Gerstein HC, Miller ME, Byington RP, et al. Effects
of intensive glucose lowering in type 2 diabetes. 66. Fulcher G, Matthews DR, Perkovic V, et al. Efficacy
N Engl J Med. 2008;358(24):254559. and safety of canagliflozin used in conjunction with
sulfonylurea in patients with type 2 diabetes
55. Duckworth W, Abraira C, Moritz T, et al. Glucose mellitus: a randomized, controlled trial. Diabetes
control and vascular complications in veterans with Ther. 2015;6(3):289302.
type 2 diabetes. N Engl J Med. 2009;360(2):12939.
67. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and
56. Patel A, MacMahon S, Chalmers J, et al. Intensive safety of canagliflozin, an inhibitor of
blood glucose control and vascular outcomes in sodium-glucose cotransporter 2, when used in
patients with type 2 diabetes. N Engl J Med. conjunction with insulin therapy in patients with
2008;358(24):256072. type 2 diabetes. Diabetes Care. 2015;38(3):40311.
57. Lipska KJ, Krumholz H, Soones T, Lee SJ. 68. Nissen SE, Wolski K. Effect of rosiglitazone on the
Polypharmacy in the aging patient: a review of risk of myocardial infarction and death from
glycemic control in older adults with type 2 cardiovascular causes. N Engl J Med.
diabetes. JAMA. 2016;315(10):103445. 2007;356(24):245771.
58. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. 69. Wilcox R, Bousser MG, Betteridge DJ, et al. Effects
Risk of mortality and adverse cardiovascular of pioglitazone in patients with type 2 diabetes with
outcomes in type 2 diabetes: a comparison of or without previous stroke: results from PROactive
patients treated with sulfonylureas and (PROspective pioglitAzone Clinical Trial In
metformin. Diabetologia. 2006;49(5):9306. macroVascular Events 04). Stroke.
2007;38(3):86573.
59. Schramm TK, Gislason GH, Vaag A, et al. Mortality
and cardiovascular risk associated with different 70. Dormandy JA, Charbonnel B, Eckland DJ, et al.
insulin secretagogues compared with metformin in Secondary prevention of macrovascular events in
type 2 diabetes, with or without a previous patients with type 2 diabetes in the PROactive
myocardial infarction: a nationwide study. Eur Study (PROspective pioglitAzone Clinical Trial In
Heart J. 2011;32(15):19008. macroVascular Events): a randomised controlled
trial. Lancet. 2005;366(9493):127989.
60. Ou SM, Shih CJ, Chao PW, et al. Effects on clinical
outcomes of adding dipeptidyl peptidase-4 71. Kernan WN, Viscoli CM, Furie KL, et al.
inhibitors versus sulfonylureas to metformin Pioglitazone after ischemic stroke or transient
therapy in patients with type 2 diabetes mellitus. ischemic attack. N Engl J Med.
Ann Intern Med. 2015;163(9):66372. 2016;374(14):132131.
61. Yu OH, Yin H, Azoulay L. The combination of 72. Zonszein J, Lombardero M, Ismail-Beigi F, et al.
DPP-4 inhibitors versus sulfonylureas with Triglyceride high-density lipoprotein ratios predict
metformin after failure of first-line treatment in glycemia-lowering in response to insulin sensitizing
Diabetes Ther (2016) 7:621639 639
drugs in type 2 diabetes: a post hoc analysis of the 81. Melikian C, White TJ, Vanderplas A, Dezii CM,
BARI 2D. J Diabetes Res. 2015;2015:129891. Chang E. Adherence to oral antidiabetic therapy in
a managed care organization: a comparison of
73. Wong HK, Ong KL, Cheung CL, Cheung BM. monotherapy, combination therapy, and
Utilization of glucose, blood pressure, and lipid fixed-dose combination therapy. Clin Ther.
lowering medications among people with type II 2002;24(3):4607.
diabetes in the United States, 19992010. Ann
Epidemiol. 2014;24(7):516.e1521.e1. 82. Hutchins V, Zhang B, Fleurence RL, Krishnarajah G,
Graham J. A systematic review of adherence,
74. Huang ES, Karter AJ, Danielson KK, Warton EM, treatment satisfaction and costs, in fixed-dose
Ahmed AT. The association between the number of combination regimens in type 2 diabetes. Curr
prescription medications and incident falls in a Med Res Opin. 2011;27(6):115768.
multi-ethnic population of adult type-2 diabetes
patients: the diabetes and aging study. J Gen Intern 83. Blonde L, San Juan ZT, Bolton P. Fixed-dose
Med. 2010;25(2):1416. combination therapy in type 2 diabetes mellitus.
Endocr Pract. 2014;20(12):132232.
75. UK Prospective Diabetes Study Group. Tight blood
pressure control and risk of macrovascular and 84. Blonde L, San Juan ZT. Fixed-dose combinations for
microvascular complications in type 2 diabetes: treatment of type 2 diabetes mellitus. Adv Ther.
UKPDS 38. BMJ. 1998;317(7160):70313. 2012;29(1):113.
76. Donnan PT, MacDonald TM, Morris AD. Adherence 85. Florez H, Luo J, Castillo-Florez S, et al. Impact of
to prescribed oral hypoglycaemic medication in a metformin-induced gastrointestinal symptoms on
population of patients with type 2 diabetes: a quality of life and adherence in patients with type 2
retrospective cohort study. Diabet Med. diabetes. Postgrad Med. 2010;122(2):11220.
2002;19(4):27984.
86. Hampp C, Borders-Hemphill V, Moeny DG,
77. Blonde L, Wogen J, Kreilick C, Seymour AA. Greater Wysowski DK. Use of antidiabetic drugs in the
reductions in A1C in type 2 diabetic patients new to U.S., 20032012. Diabetes Care.
therapy with glyburide/metformin tablets as 2014;37(5):136774.
compared to glyburide co-administered with
metformin. Diabetes Obes Metab. 87. Woo V. Empagliflozin/linagliptin single-tablet
2003;5(6):42431. combination: first-in-class treatment option. Int J
Clin Pract. 2015;69(12):142737.
78. Pan F, Chernew ME, Fendrick AM. Impact of
fixed-dose combination drugs on adherence to 88. Lewin A, DeFronzo RA, Patel S, et al. Initial
prescription medications. J Gen Intern Med. combination of empagliflozin and linagliptin in
2008;23(5):6114. subjects with type 2 diabetes. Diabetes Care.
2015;38(3):394402.
79. Thayer S, Arondekar B, Harley C, Darkow TE.
Adherence to a fixed-dose combination of 89. Rosenstock J, Inzucchi SE, Seufert J, Fleck PR,
rosiglitazone/glimepiride in subjects switching Wilson CA, Mekki Q. Initial combination therapy
from monotherapy or dual therapy with a with alogliptin and pioglitazone in drug-naive
thiazolidinedione and/or a sulfonylurea. Ann patients with type 2 diabetes. Diabetes Care.
Pharmacother. 2010;44(5):7919. 2010;33(11):24068.
80. Cheong C, Barner JC, Lawson KA, Johnsrud MT. 90. Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The
Patient adherence and reimbursement amount for incidence and costs of hypoglycemia in type 2
antidiabetic fixed-dose combination products diabetes. Am J Manag Care. 2011;17(10):67380.
compared with dual therapy among Texas
Medicaid recipients. Clin Ther.
2008;30(10):1893907.
Reproduced with permission of the copyright owner. Further reproduction prohibited without
permission.